<DOC>
	<DOCNO>NCT01853423</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy 0.1 % formulation rapamune cream child Tuberous Sclerosis Complex ( TSC ) , age 3 year old , facial angiofibromas would benefit treatment .</brief_summary>
	<brief_title>Tuberous Sclerosis Complex : Facial Angiofibroma Skin Cream</brief_title>
	<detailed_description>This open label , prospective single center study . Patients see regional Tuberous Sclerosis Complex Clinic facial angiofibromas would benefit cream wish involve study would enrol . We anticipate enrol 12-15 patient first year . Patients picture facial angiofibromas take immediately prior entry study . They prescribe 0.1 % rapamune topical formulation apply twice daily skin first two week daily . If level 0 , re-check serum lipid , cbc , repeat level every three-four month monitor patient symptom . Patients return one month three month obtain serum rapamune level along picture , see intermittently throughout first year photograph face take one month visit , 3 month visit , six month visit twelve month visit . We ask parent side effect medication entire time patient use topical rapamune . We monitor facial lesion well . We assess skin sensitivity , pain , erythema , pruritus . If skin irritation result drug , stop use drug . Parents sign inform consent allow child 's picture take allow u summarize data publication end study . This study first study use consistent formulation make 0.1 % rapamune cream , perform direction Dr. Almoazen University Tennessee Health Science Center ( UTHSC ) College Pharmacy compound laboratory . Only patient think reliable follow visit use cream appropriately enrol study . This study meet FDA criterion Investigational New Drug ( IND ) exemption . The adverse event note package insert rapamune cream base systemic administration medication , primarily adults disease . In clinical experience , topical use absorption note side effect .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Facies</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Angiofibroma</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patient / legally authorize representative ( LAR ) must sign date approve informed consent prior study participation initiation study procedure . If appropriate , patient give write verbal consent . Surrogate consent obtain utilize `` legally authorize representative ( LAR ) '' . The LAR must adult exhibit special care concern subject , familiar subject 's personal value , reasonably available , willing serve . No person identify protective order court order direct person avoid contact subject shall eligible serve subject 's LAR . Identification LAR normally make use follow order descend preference : Conservator , guardian , attorney fact , subject 's spouse ( unless legally separate ) , subject 's adult child , subject 's parent , subject 's adult sibling , adult relative subject , adult familiar patient 's personal value , reasonably available , willing serve . 1 . Patient must diagnosis Tuberous Sclerosis Complex . 2 . Female male patient age 3 year . 3 . Female subject child bear potential must pregnant must undergo pregnancy test , must agree use appropriate contraceptive method Patients exclude entry study follow true : 1 . Patient history drug allergy rapamune . 2 . Patient pregnant lactating . 3 . Subject receive therapy Rapamycin . 4 . Subject receive form immunosuppression previously experience immune dysfunction . 5 . Subject currently participate participate within Last 30 day clinical trial involve investigative drug . 6 . Subject dermatologic condition would preclude prevent adequate assessment change facial angiofibromas . 7 . Subject laser surgery , cryotherapy , dermatologic treatment facial angiofibromas within previous 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Rapamune</keyword>
	<keyword>Topical</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficiency</keyword>
	<keyword>Angiofibroma</keyword>
	<keyword>Skin Cream</keyword>
</DOC>